In vitro diagnostics company QuidelOrtho has been formed through the merger combining Quidel and Ortho Clinical Diagnostics Holdings.. The new company, headquartered in San Diego, generated more than $3.5 billion in combined revenues in 2021 and has approximately 6,000 employees. QuidelOrtho will trade on the Nasdaq under the symbol QDEL.
Under the terms of the agreement governing the transaction, former Ortho shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho common share. Former Quidel stockholders received one share of QuidelOrtho common stock for each share of Quidel common stock. The QuidelOrtho board is composed of 8 former Quidel board members and 4 former Ortho board members. Read more.
